biostudies-literatureJarvis JNStyrelsen för Internationellt UtvecklingssamarbeteEuropean and Developing Countries Clinical Trials PartnershipFIC NIH HHSDepartment for International Development, UK GovernmentDepartment for International DevelopmentMedical Research CouncilNational Institute for Health Research (NIHR)NINDS NIH HHSWellcome Trust1109-1120https://www.ebi.ac.uk/biostudies/studies/S-EPMC7612678biostudies-literatureUnknown386(12)<h4>Background</h4>Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa. Whether a treatment regimen that includes a single high dose of liposomal amphotericin B would be efficacious is not known.<h4>Methods</h4>In this phase 3 randomized, controlled, noninferiority trial conducted in five African countries, we assigned HIV-positive adults with cryptococcal meningitis in a 1:1 ratio to receive either a single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day) or the current World Health Organization-recommended treatment, which includes amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytosThe New England journal of medicineSingle-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.PMC7612678203135214321206007K01 TW010268RP-2017-08-ST2-012214321/Z/18/ZR01 NS086312TRIA2015-1092MC_PC_MR/P006922/1MR/P006922/1203135/Z/16/Z098316Kumwenda MKugonza FMasina NKukacha CJarvis JNShah RMorar TChitulo GWilliams DSchutz CSsemusu MTugume LMnguni TApril SMwarumba TKiiza DTegha GChimang'anga WZambasa ANdyetukira JRutakingirwa MKHafeez SNdalama MRulaganyang ISadiq AMuthoga CNaude JLipenga BKanyama CMmipi RKufa PMudzingwa SMpoza EMaya CLawrence DSMolloy SFPonatshego PMphande CYoussouf NZinyandu TAlice AMaughan DBoloko LMoyo MRwomushana IMhango WKyepa HMawoko NLalloo DGGoodall JChimphambano TLechiile KStott KLortholary ODavids LMuzoora CNgoma DKagimu EOkirwoth MSturny-Leclere AChome NSebesho LGoliath RNicholas SShey MSayed SSwanepoel LBoyer-Chammard TRodgers AKadzilimbile AJjunju SComins KInyakuwa CBookholane HAkampurira ASingh AOliphant IAlanio ASiamisang KDromer FMsumba LMwesigye JMutata CKumwenda EGakuru JCresswell FSingini AKazembe MRukundo JAtwine LKachitosi TGondwe EWang DKisembo JZambezi JKamanga BLoyse AMunthali TAhimbisibwe CTadeo KBekiswa AEmily NChawinga CMoosa SBoyd KHosseinipour MCMilburn JDziwani EHoffman RChasweka MChen TGriffin PCrede THlungulu SMtisi TTlhako NNamujju OSsebambulidde KRhein JKateta SMzinganjira HNsangi LMeya DBAmbition Study GroupBuzaare PMuyise RLuggya TNdaferankhande JHope WKossam EMeintjes GTsholo KMoyo CKasibante JGwin MMbangiwa TLeeme TMwandumba HCMosepele MLule AKariisa SNiwamanya SJaffar SStambuli ABoulware DRStead GChiwoko Lvan Widenfelt EHarrison TSTukundane AGondo SNuwagira EChikaonda TMusubire AKwizera RSeatla KMpalali MSimwinga LHlupeni ANdhlovu CELaker ECollins MMakaha EBanda TfalseSingle-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.<h4>Background</h4>Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa. Whether a treatment regimen that includes a single high dose of liposomal amphotericin B would be efficacious is not known.<h4>Methods</h4>In this phase 3 randomized, controlled, noninferiority trial conducted in five African countries, we assigned HIV-positive adults with cryptococcal meningitis in a 1:1 ratio to receive either a single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day) or the current World Health Organization-recommended treatment, which includes amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytos2022-01-01T00:00:00Z2022 Mar2025-04-04T07:44:23.977Z2025-04-04T07:44:23.977ZS-EPMC76126783532064210.1056/NEJMoa2111904